Clincosm LogoSign in Get a demo

FARPRESTO: PREdictive Risk Factors of Conversion Into Idiopathic RBD. Italian Study

Sponsor
University of Cagliari (Other)
Overall Status
Recruiting
CT.gov ID
NCT05262543
Collaborator
University of Bologna (Other), University of Genova (Other), University of Pavia (Other)
300
Enrollment
1
Location
176.2
Anticipated Duration (Months)
1.7
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

REM Sleep Behavior Disorder (RBD) is a REM sleep parasomnia first described in 1986 and characterized by the loss of physiological muscle atonia typical of REM sleep and by the presence of abnormal, sometimes violent, motor activity often related to dream content The observed motor behaviors are often associated to vivid dreams, characterized by an aggressive-defensive content, even if pleasant dreams have been described, resulting in non-violent behaviors. Diagnosis of RBD requires video-polysomnographic recording (vPSG) at a Sleep Center, essential to identify and quantify the complete or intermittent loss of physiological muscle atonia during REM sleep (REM sleep without atonia, RSWA) and record any related motor behaviors. The exact prevalence of RBD in the general population is not known and it seems underrated, but is estimated to be 0.3-1.15%. RBD is defined as idiopathic or isolated (iRBD) when it is not associated with other neurological diseases. The so-called symptomatic RBD, on the other hand, can occur in association with neurodegenerative diseases of the spectrum of alpha-synucleinopathies which include Parkinson's Disease (PD), Multiple System Atrophy (AMS), and Lewy Body Dementia (DLB). In recent years, several follow-up studies on large cohorts of iRBD patients have shown that the idiopathic form evolves towards a symptomatic form in most cases. More precisely, the risk of developing an alpha-synucleinopathies increases over time, with a conversion rate of up to 90% in some studies at 14 years. RBD represents an early marker of neurodegeneration, like a unique open window on the initial, pre-symptomatic phase of alpha-synucleinopathies, which could allow the use of neuroprotective therapies, as soon as they are available. Several longitudinal studies indicated older age, presence of hyposmia, abnormal color vision, minimal extrapyramidal motor signs, mild cognitive impairment, autonomic disturbances, and severity of loss of RSWA as risk factors for neurodegeneration. However, most studies investigated biomarkers separately, with retrospective study designs, in small cohorts or without a rigorous harmonization between centers in the case of multicenter studies.

To date, however, there is no reliable pool of biomarkers that predict the phenoconversion into α-synucleinopathy, the timing in which this can occur, and the phenotype of α-synucleinopathy. Furthermore, despite clinical and research evidence suggesting that iRBD is a heterogeneous disorder little attention was paid to different iRBD phenotypes and currently, there are no relevant data on the impact of iRBD on quality of life.

Actually, through neural network analysis approaches, it is possible to find out complex correlations between data from different sources (i.e., clinical examinations, questionnaires, biological data, imaging and neurophysiological techniques, etc.) and to identify subgroups of patients sharing the same substantial characteristics. Identifying different iRBD phenotypes through established as well as innovative biomarkers and standardized measures of wellbeing is crucial to better understanding alpha-synucleinopathies, developing targeted interventions, and reducing the disease burden.

To this aim, clinical, biological, neurophysiological, neuropsychological and imaging biomarkers need to be prospectively collected, according to standardized and harmonized procedures. This would significantly increase our understanding of the physiopathological processes of alpha-synucleinopathy from the prodromal phase. Indeed, identifying phenotype clusters with both consolidated and innovative biomarkers may lay the groundwork for a reliable characterization of iRBD patients, likely providing the basis for an efficient stratification of patients longitudinally followed.

Several disease-modifying therapies are now in development, including but not limited to monoclonal antibodies against alpha-synucleinopathy. Prodromal synucleinopathy patients, such as those with iRBD, are the ideal target to test disease-modifying therapies because the neurodegeneration is still in an early stage and the likelihood to rescue both brain structures and function is higher. The last aim of the FarPResto study is to have a trial-ready cohort of iRBD patients, collected with standardized and harmonized procedures, to be enrolled in upcoming disease-modifying trials.

The FARPRESTO project is endorsed by the Italian Association of Sleep Medicine (AIMS) and by The RBD_Patients society (www.sonnomed.it)

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    300 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Redictive Risk Factors of Conversion Into Idiopathic RBD. Italian Study [FAttori di Rischio PREdittivi di Conversione Nell'RBD Idiopatico. STudio ItalianO
    Actual Study Start Date :
    May 25, 2020
    Anticipated Primary Completion Date :
    Mar 31, 2022
    Anticipated Study Completion Date :
    Jan 31, 2035

    Outcome Measures

    Primary Outcome Measures

    1. Identification of predictive risk factors of phenoconversion in patients with iRBD [May 25, 2020 - January 31, 2035]

      In order to increase our understanding on the physiopathological processes of alpha-synucleinopathy from the prodromal phase clinical, biological, neurophysiological, neuropsychological and imaging biomarkers need to be prospectively collected, according to standardized and harmonized procedures. Moreover, identifying phenotype clusters with both consolidated and innovative biomakers may lay the groundwork for a reliable characterization of iRBD patients, likely providing the basis for an efficient stratification of patients to be longitudinally followed.

    Secondary Outcome Measures

    1. Description of the socio-demographic and clinical characteristics of patients diagnosed with iRBD [May 25, 2020 - January 31, 2035]

      Data on socio-demographic and clinical characteristics of patients diagnosed with iRBD will be collected and analyzed.

    2. Collection of longitudinal data about the development of alpha-synucleinopathies and estimation of the conversion rate at 3, 5, 7, and 10 years [May 25, 2020 - January 31, 2035]

      Information about the conversion rate at 3, 5, 7, and 10 years to neurodegenerative pathologies of the spectrum of alpha-synucleinopathies (Parkinson's Disease, Multiple System Atrophy and Lewy Body Dementia) will be collected and evaluated.

    3. Evaluation of the impact of iRBD on the quality of life and sleep [May 25, 2020 - January 31, 2035]

      The impact of iRBD on the quality of life and sleep will be assessed through the administration of validated questionnaires.

    4. Assessment of the correlation between phenoconversion, cognitive performance and loss of normal muscle atony during REM sleep [May 25, 2020 - January 31, 2035]

      The results of cognitive performance tests, video-polysomnographic recording and their connection with phenoconversion will be investigated

    5. Identification of RBD phenotypes through different biomarkers [May 25, 2020 - January 31, 2035]

      RBD phenotypes will be identified evaluating clinical, biological,neurophysiological, neuropsychological and imaging biomarkers.

    6. Validation of vPSG criteria for RBD diagnosis [May 25, 2020 - January 31, 2035]

      vPSG criteria for RBD diagnosis will be validated

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    • Age: major of 18 years old

    • iRBD diagnosis, according to diagnostic criteria of the ICSD second and third edition

    Exclusion Criteria:
    • Impossibility to provide or withdraw informed consent and inability to read, write and understand the purpose and modality of the study.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Centro Interdipartimentale di Medicina del Sonno, Università degli studi di Cagliari Cagliari Italy 09042

    Sponsors and Collaborators

    • University of Cagliari
    • University of Bologna
    • University of Genova
    • University of Pavia

    Investigators

    • Principal Investigator: Monica Puligheddu, MD,PhD, University of Cagliari

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Monica Puligheddu, Professor of Neurology, University of Cagliari
    ClinicalTrials.gov Identifier:
    NCT05262543
    Other Study ID Numbers:
    • FarPresto01
    First Posted:
    Mar 2, 2022
    Last Update Posted:
    Mar 2, 2022
    Last Verified:
    Feb 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Monica Puligheddu, Professor of Neurology, University of Cagliari
    atonia
    neurodegeneration
    Additional relevant MeSH terms:
    REM Sleep Behavior Disorder
    Mental Disorders

    Study Results

    No Results Posted as of Mar 2, 2022